David h. Persing - Nanotechnology

Author Information

David H. Persing is affiliated with Cepheid AB, located in Sunnyvale, CA 94089, USA. He has made significant contributions to the fields of diagnostics and biomarker discovery, particularly in relation to infectious diseases such as tuberculosis and Human Papillomavirus (HPV).

Research Contributions

David H. Persing has authored numerous papers that focus on the development and clinical evaluation of diagnostic assays. His research has a strong emphasis on improving the diagnostic accuracy and utility of biomarkers for various diseases. Notable contributions include studies on blood-based assays for tuberculosis treatment monitoring, pharmacogenomic assays for guiding isoniazid dosing, and modifications to HPV assays for cervical cancer screening in low-resource settings. His recent work also includes research on SARS-CoV-2 diagnostics and public perception of infection prevention.

Aliases

David H. Persing is also known by several aliases, including David H. Persing, D H Persing, D. Persing, D.h Persing, David Persing, D. H. Persing, and D. h. Persing.

Publication and Citation Metrics

Metric	Value
Citation Count	32,687
h-index	85
Paper Count	331

Publications:

Clinical utility of reflex testing with cancer biomarkers to improve diagnostic accuracy of primary Human Papillomavirus screening.

DOI: 10.1158/1055-9965.EPI-21-0972

Year: 2022

A Novel Blood-Based Assay for Treatment Monitoring of Tuberculosis

DOI: 10.21203/RS.3.RS-384297/V1

Year: 2021

A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.

DOI: 10.1164/rccm.202103-0564OC

Year: 2021

Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: a diagnostic accuracy study

DOI: 10.1101/2020.12.27.20248917

Year: 2021

Blood-based host biomarker diagnostics in active case finding for pulmonary tuberculosis: A diagnostic case-control study

DOI: 10.1016/j.eclinm.2021.100776

Year: 2021

A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosingfor tuberculosis treatment

DOI: 10.1101/2021.01.17.21249995

Year: 2021

A novel blood-based assay for treatment monitoring of tuberculosis

DOI: 10.1186/s13104-021-05663-z

Year: 2021

Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study.

DOI: 10.1016/S2214-109X(19)30527-3

Year: 2020

Xpert MTB/XDR: A ten-color reflex assay suitable for point of care settings to detect isoniazid-, fluoroquinolone-, and second line injectable drug-resistance directly from Mycobacterium tuberculosis positive sputum

DOI: 10.1101/2020.09.08.288787

Year: 2020

nnn The SARS-CoV-2 outbreak: diagnosis, infection prevention, and public perception

DOI:

Year: 2020

What Challenges are Associated with Imaging Nanoparticles?

What Are the Benefits of Using Nanotechnology in Surface Hardening?

Why is Interoperability Important in Nanotechnology?

What is Nanotechnology in Storage Technologies?

What are Sulfides in Nanotechnology?

What is a Top-Down Approach?

What Are the Benefits of Preventive Maintenance?

What are the Challenges in Nanotechnology Patent Searches?

Who are the Key Researchers Involved?

How is Capacitance Measured?

Partnered Content Networks

Relevant Topics